Cheilitis granulomatosa

2011 ◽  
Vol 17 (10) ◽  
Author(s):  
Amy E Rose ◽  
Marie Leger ◽  
Julie Chu ◽  
Shane Meehan
1966 ◽  
Vol 94 (5) ◽  
pp. 660-661
Author(s):  
M. A. Storkan

2001 ◽  
Vol 110 (10) ◽  
pp. 964-967 ◽  
Author(s):  
Gerd Jürgen Ridder ◽  
Milo Fradis ◽  
Erwin Löhle

Cheilitis granulomatosa Miescher is a rare condition of unknown cause characterized by intermittent lip swelling that gradually persists and causes cosmetic deformity. We report the case of a young woman with cheilitis granulomatosa as a monosymptomatic manifestation of Melkersson-Rosenthal syndrome successfully treated by the antileprosy agent clofazimine, and propose clofazimine as an alternative treatment in cases refractory to corticosteroids. The differential diagnosis and current methods of treatment are summarized, and the literature is reviewed and discussed.


2012 ◽  
Vol 18 (6) ◽  
Author(s):  
Bhushan Sevakram Madke ◽  
Deepti Ghia ◽  
Reshma Gadkari ◽  
Chitra Nayak

Author(s):  
Nils Peters ◽  
Martin Dichgans ◽  
Sankar Surendran ◽  
Josep M. Argilés ◽  
Francisco J. López-Soriano ◽  
...  

2019 ◽  
Vol 11 (3) ◽  
pp. 249-255 ◽  
Author(s):  
Thanapon Sutharaphan ◽  
Kumutnart Chanprapaph ◽  
Vasanop Vachiramon

Cheilitis granulomatosa (CG) is a rare idiopathic condition with painless lip swelling, characterized by non-necrotizing granulomatous inflammation in the absence of other identifiable causes such as Crohn’s disease, sarcoidosis, foreign body reaction, or infection. CG may precede the presentation of Crohn’s disease after long-term follow-up. Spontaneous remission of CG rarely occurs. To date, given the rarity of CG, there is no gold standard treatment. Recommended treatments are supported by small studies, case reports/series, and expert opinions. Glucocorticoids are the first-line therapy in the acute stages of the disease; however, recurrence commonly occurs. Previously, methotrexate (MTX) showed a beneficial effect on orofacial swelling in a case of CG accompanied by Crohn’s disease. We present a patient with CG without Crohn’s disease. He was treated with oral MTX in combination with intralesional corticosteroid injection on one side of the lip. The injected side showed improvement, while lip swelling on the noninjected area remained unchanged after 3 months of treatment. Therefore, CG is refractory to treatment with MTX from our experience. Further studies regarding the optimum dosage of MTX is needed.


2020 ◽  
Vol 18 (6) ◽  
pp. 611-613
Author(s):  
Alexandra Gronostay ◽  
Luisa Hellmich ◽  
Heinrich Rasokat ◽  
Nicolas Hunzelmann

Sign in / Sign up

Export Citation Format

Share Document